Navigation Links
NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
Date:3/3/2008

SOPHIA ANTIPOLIS, France, March 3 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the initiation of two large clinical pharmacology studies in the United States, which will assess the blood pressure profile of naproxcinod in comparison to ibuprofen and naproxen, using the Ambulatory Blood Pressure Monitoring (ABPM) technique. These separate studies, 12 and 16 weeks in duration, will together recruit a total of around 420 osteoarthritis patients with controlled hypertension and results are projected in Q4 2008. Naproxcinod is NicOx' lead investigational drug and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is currently in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis, with results of the last two phase 3 studies anticipated in the second half of 2008.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen and naproxen, are commonly used by osteoarthritis patients to control their chronic pain, inflammation and stiffness and significantly improve quality of life for millions of people. However, these important products have the tendency to raise blood pressure to an extent that may increase the rate of serious cardiovascular adverse events (see NOTE 1).

Pascal Pfister MD, Chief Scientific Officer and Head of Research and Development at NicOx, said: "Our development program for naproxcinod aims to address the safety concerns surrounding anti-inflammatory agents and blood pressure, which represents a serious medical issue. Previous studies using the ABPM technique and Office Blood Pressure Measurements have suggested that naproxcinod may have an improved blood pressure profile compared to existing anti-inflammatory drugs, which would greatly facilitate its future adoption by physicians and patients. These two new studies will provide important data in a relevant population of chronically treated osteoa
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
2. NicOx Opens U.S. Headquarters in New Jersey
3. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
6. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
7. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Stemedica ... of clinical grade biological products as licensed by the State of California Food and Drug ... latest scientific discoveries at the 2009 World Stem Cell Summit. , ... San Diego, CA (PRWEB) Aug 27, 2009 -- ...
... , The statement below is from Pete Nicholas, Chairman ... employees and its Board of Directors. , , ... remarkably broad spectrum of issues. Foremost among them was his long and ... , He was a tireless advocate for patients, rights and for ...
... , CHICAGO, Aug. 26 Ajinomoto Food ... adding food product development capabilities. The Application Center North America ... , The ACNA mission is to develop and ... technology applications will be the initial focus of the Center: ...
Cached Biology Technology:Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 2Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 3Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 4Boston Scientific Statement on the Passing of Senator Edward Kennedy 2
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... been accompanied by more years of perfect health, reveals new research ... . Indeed, a 20-year-old today can expect to live one ... a decade ago, even though life expectancy has grown. From ... 85 doubled, from about a 20 percent chance to a 40 ...
... BOSTON Boston University biology professor Richard Primack, ... completed an analysis of the changing arrival dates of ... Henry David Thoreau from the 1850,s. This research builds ... plants in Concord respond rapidly to temperature and are ...
... 2010 Elsevier ( www.elsevier.com ), a world-leading ... and services, today announced that as a result ... HealthMash, is now available on SciVerse Applications beta ... to provide insights to scientific researchers with relevant ...
Cached Biology News:We spend more time sick now than a decade ago 2We spend more time sick now than a decade ago 3WebLib develops application for Elsevier's SciVerse applications 2
... 13(S)-HODE-d4 contains 4 deuterium atoms at the 9, ... for use as an internal standard for the ... 13(S)-HODE is produced by incubation of linoleic acid ... shown to inhibit the adhesion of tumor cells ...
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: